About Dylan Sammut
Dylan joined Irving Levin in October 2018 as a Research and Editorial Associate and is responsible for reporting on mergers and acquisitions in the healthcare sector. He graduated from Alfred University in May 2014 with a degree in English and Political Science. He currently lives in Bridgeport, CT with his fiancé and his overweight cat, Kimba, and in his free time he plays video games, reads, writes, and hikes on the weekends all year around.
by Dylan Sammut | Jul 20, 2021 8:42 am | eHealth
With the support of three financial backers, Waystar has been steadily expanding over the past few years. The company specializes in revenue cycle management services and partners with more than 450,000 providers, 750 health systems and hospitals, and 5,000 payers and... Read More »
by Dylan Sammut | Jul 13, 2021 9:33 am | Healthcare Market Updates
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our new LevinPro Healthcare and LTC platform, which is updated daily to provide our subscribers with the most... Read More »
by Dylan Sammut | Jul 13, 2021 8:35 am | Other Services
After acquiring University Health Care in mid-June for $600 million, Cano Health (NYSE: CANO) has already struck another deal. Cano Health announced last week it is acquiring Doctor’s Medical Center (DMC), which provides integrated, innovative care to Medicare,... Read More »
by Dylan Sammut | Jul 13, 2021 8:33 am | Home Health & Hospice
The home health and hospice giant Amedisys, Inc. (NASDAQ: AMED) is back with a new deal. Earlier in July, the company announced it was buying Contessa Health, which specializes in hospital-at-home and skilled nursing facility at-home services, for $250 million, or... Read More »
by Dylan Sammut | Jul 13, 2021 8:32 am | CRO, Other Services
It looks like contract research organizations are still in high demand. EQT Private Equity and Goldman Sachs Asset Management Private Equity are teaming up to acquire Parexel from Pamplona Capital Management for $8.5 billion. Parexel is a leading global clinical... Read More »